Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

被引:5
|
作者
Poindexter, Alfred [2 ]
Reape, Kathleen Z. [1 ]
Hait, Howard [1 ]
机构
[1] Duramed Res Inc, Bala Cynwyd, PA 19004 USA
[2] Baylor Coll Med, Houston, TX 77011 USA
关键词
desogestrel; low-dose estrogen; hormone free interval; oral contraception;
D O I
10.1016/j.contraception.2008.04.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The study was conducted to evaluate the efficacy and safety for the prevention of pregnancy of a 28-day oral contraceptive (OQ containing 150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days followed by 7 days of 10 mcg EE (Cette-28). Study Design: A 6-month, prospective, multicenter, single-arm study was conducted in 1302 women aged 18-45 years. Results: Over six cycles of treatment, the cumulative risk of pregnancy among all treated subjects (n= 1262) was 0.9%. The Pearl Index for women 18-35 years of age (n=1042) was 2.20, including 9 pregnancies with estimated conception dates during active drug ingestion or up to 7 days after the last combination tablet. The rate of unscheduled bleeding was low and the duration of scheduled bleeding was approximately 2 days during each of the six treatment cycles. The safety profile was similar to what has been reported for other OCs. Conclusion: This low-dose, 28-day OC incorporating 7 days of 10 mcg EE during the hormone free interval is effective and safe for the prevention of pregnancy and is well-tolerated by women. (0 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [1] Bleeding patterns in users of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo compared to a conventional 28-day regimen
    Feldman, R.
    Reape, K. Z.
    Hait, H.
    CONTRACEPTION, 2007, 76 (02) : 171 - 172
  • [2] Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo
    Davis, M.
    Reape, K. Z.
    Hait, H.
    CONTRACEPTION, 2007, 76 (02) : 172 - 172
  • [3] Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo
    Anderson, Freedolph D.
    Feldman, Robert
    Reape, Kathleen Z.
    CONTRACEPTION, 2008, 77 (02) : 91 - 96
  • [4] Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive
    Reape, Kathleen Z.
    Diliberti, Charles E.
    Hendy, Christopher H.
    Volpe, Edward J.
    CONTRACEPTION, 2008, 77 (01) : 34 - 39
  • [5] Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol
    Kroll, Robin
    Ackerman, Ronald
    Feldman, Robert
    Howard, Brandon
    Weiss, Herman
    Hsieh, Jennifer
    Ricciotti, Nancy
    CONTRACEPTION, 2016, 93 (03) : 249 - 256
  • [6] The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol
    Kroll, Robin
    Reape, Kathleen Z.
    Margolis, Marya
    CONTRACEPTION, 2010, 81 (01) : 41 - 48
  • [7] The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg
    Bocci, A.
    Spielniann, D.
    Azzini, Pr
    Guaschino, Pr
    Affronti, G.
    Villani, Pr
    Boselli, Pr
    Genazzani, Pr
    Flamigni, Z. C.
    Omodei, U.
    Bolis, P.
    Marsoni, V.
    Luerti, M.
    Simenel, J. L.
    Ouvry-Neveu, B.
    Andre, G.
    David, S.
    Durand, J. L.
    Ehret-Mentre, C.
    Gensburger, J. M.
    Goetzmann, P.
    Jung-Faerber, S.
    Keller, D.
    Lempereur, M.
    Plumere, C.
    Spielmann, A.
    Katz, J. L.
    Sebaoun, J.
    Belaisch, J.
    Hammer, F.
    Salama, B.
    Aissaoui, S.
    Taube, A. M.
    Nakache, H.
    Soria, J.
    Joffo, M.
    Lardenois, H.
    Leclerc, P.
    Ponsar, C.
    Saubry-Bobet, V.
    Blaiset, E.
    Veyres, F.
    Clamp, M.
    Menon, K. V. K.
    Moran, D. G.
    Randall, S.
    Shaw, P. J.
    Bruni, V.
    Massobrio, M.
    Crosignani, P.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 1999, 4 : 9 - 15
  • [8] An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
    Akin, M
    Archer, D
    Berga, S
    Burns, L
    Calkins, J
    Davis, A
    Draeger, M
    Freidensen, H
    Funk, S
    Giesler, C
    Gordon, S
    Katz, D
    Khairi, S
    Ledger, W
    Lenihan, J
    London, R
    McQuarrie, H
    Medina, H
    Mercer, L
    Milhalov, L
    Montgomery, M
    Notelovitz, M
    Parker, G
    Phillips, E
    Reza, L
    San Fillippo, J
    Saxena, B
    Singh, M
    Soltes, B
    Soper, H
    Speroff, L
    Summers, P
    Trupin, S
    Weissberg, S
    Willems, J
    Young, R
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : S2 - S8
  • [9] The safety and efficacy of low-dose oral contraceptives
    van der Westhuizen, Elmarie
    van der Merwe, Elsabe
    SA PHARMACEUTICAL JOURNAL, 2010, 77 (01) : 22 - 28
  • [10] The safety and efficacy of low-dose oral contraceptives
    Van der Westhuizen, E.
    Van der Merwe, E.
    SOUTH AFRICAN FAMILY PRACTICE, 2011, 53 (05) : 403 - 411